Join Now

Yearly Archives: 2025

Altesa BioSciences and bioMérieux Announce Collaboration for Altesa’s Upcoming Phase 2B COPD Clinical Trial

Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites.

Posted in BioUtah News | Tagged | Comments Off on Altesa BioSciences and bioMérieux Announce Collaboration for Altesa’s Upcoming Phase 2B COPD Clinical Trial

Owlet Makes Premium Monitoring Possible for Every Family With New Dream Sight™ Video Monitor

Owlet’s new release creates the ultimate baby monitoring system for video, sleep, and medical-grade health tracking.

Posted in BioUtah News | Tagged | Comments Off on Owlet Makes Premium Monitoring Possible for Every Family With New Dream Sight™ Video Monitor

BioUtah Member Appreciation BBQ 2025 Recap

BioUtah Member Appreciation BBQ 2025 Recap

Posted in BioUtah News | Comments Off on BioUtah Member Appreciation BBQ 2025 Recap

Kimbell & Associates: Trump Administration Issues MAHA Strategy Report of Recommendations to President Trump

Kimbell & Associates: Trump Administration Issues MAHA Strategy Report of Recommendations to President Trump

Posted in BioUtah News | Tagged | Comments Off on Kimbell & Associates: Trump Administration Issues MAHA Strategy Report of Recommendations to President Trump

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2.

Posted in BioUtah News | Tagged | Comments Off on Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

Salt Lake City Angels Invests in Freyya

Salt Lake City Angels Invests in Freyya

Posted in BioUtah News | Tagged | Comments Off on Salt Lake City Angels Invests in Freyya

Owlet Extends Global Reach with Launch of Medically-Certified Dream Sock™ to South Africa

The wearable baby monitor trusted by millions globally expands reach to three continents, including North America, Europe, and now Africa.

Posted in BioUtah News | Tagged | Comments Off on Owlet Extends Global Reach with Launch of Medically-Certified Dream Sock™ to South Africa

Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor

Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment platform

Posted in BioUtah News | Tagged | Comments Off on Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor

BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative

BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative

Posted in BioUtah News | Tagged | Comments Off on BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative

PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy

Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste® market strategy

Posted in BioUtah News | Tagged | Comments Off on PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.

Posted in BioUtah News | Tagged | Comments Off on Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Halia Therapeutics Published in Journey of Drug Targeting

Halia Therapeutics Published in Journey of Drug Targeting

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics Published in Journey of Drug Targeting